Recent Updates
Recently added Catalysts

Travere Therapeutics, Inc.

TVTXFDA catalysts, PDUFA dates & pipeline intelligence
$51.1
▲ +1.4 · +2.82%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full TVTX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $22.5952W HIGH $68.73
Volume
1.40 M
Value Traded
70.66 M
Short % Float
10.26%
Days to Cover
4.7
-1.81%Week
+1.21%1 Month
-22.53%3 Month
+17.5%6 Month
+141.21%5 Year
-92.41%All Time

Cash Data

Unlock TVTX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
4.91 B
EPS (TTM)
-1.27
P/E Ratio
-
Ent. Value
5.04 B
Total Shares
95.99 M
Float Shares
93.16 M
Insiders
2.96%
Institutions
115.29%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
IND Submission
civorebrutinib (EVER001)
Primary membranous nephropathy (pMN), immune-mediated FSGS, minimal change disease (MCD), other immune-mediated kidney diseases
INDSmall MoleculesNephrology
Unlock every TVTX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

TVTX Catalyst Timeline

Dated clinical, regulatory and corporate events for Travere Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Travere Therapeutics, Inc.

556Total events
15Upcoming
128Tier-1 (high impact)
2015 to 2037Coverage

Upcoming catalysts 2

T2Management Change
Subscribe to view catalyst details
T2Management Change
Subscribe to view catalyst details

Event history 50

●Quarterly UpdateCorporate
Travere Therapeutics reports third quarter 2026 financial results
▲Biomarker DataSparsentanApprovedClinical Data
PROTECT biomarker data: greater reductions in sCD163, BAFF, C5b-9, IL-6 vs irbesartan through Week 110
IgA nephropathysource ↗
▲Oral PresentationSparsentanApprovedPresentation
Oral presentation of PROTECT biomarker data at ASN Kidney Week 2026
IgA nephropathysource ↗
●Grant / FundingCorporate
Inducement equity grants of 178,580 shares to 33 new employees
◆Oral PresentationSparsentanApprovedPresentation
Five oral presentations of new FILSPARI data at ASN Kidney Week 2026
IgA nephropathy and focal segmental glomerulosclerosissource ↗
◆Poster PresentationSparsentanApprovedPresentation
Nine new FILSPARI data presentations at ASN Kidney Week 2026
IgA nephropathy and focal segmental glomerulosclerosissource ↗
▲Subgroup AnalysisSparsentanApprovedClinical Data
DUPLEX post hoc analysis in FSGS without nephrotic syndrome: 3x higher complete remission, 75% lower kidney failure vs irbesartan
Focal Segmental Glomerulosclerosissource ↗
▲Biomarker DataSparsentanApprovedClinical Data
PROTECT urinary biomarker analysis: rapid and sustained reductions in macrophage, B-cell, inflammation and complement markers
IgA Nephropathysource ↗
▲Full ResultsSparsentanApprovedClinical Data
Final SPARTAN data: 75% complete proteinuria remission and eGFR stabilization at 2 years
IgA Nephropathysource ↗
▲Patent GrantedSparsentanApprovedIP / Competition
USPTO issues Notice of Allowance for U.S. Patent Application No. 19/253,120 covering methods of using sparsentan in FSGS
focal segmental glomerulosclerosis (FSGS)source ↗
Unlock the full TVTX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How TVTX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-23FILSPARI (sparsentan) Phase 3 data presentation Phase 3
Unlock 9 more TVTX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 19%
Small Cap
(rank 139 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
ProductRevenuePrior periodChange
FILSPARI
Tiopronin products
Showing 5 of 10 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
L-Citrulline Small MoleculesNCT06989567Sickle Cell DiseasePhase 3 NOT YET_RECRUITING 120Jun 1, 2029
Pegtibatinase Enzyme Replacement Therapies (ERT)NCT06431893HomocystinuriaPhase 3 ENROLLING BY_INVITATION 209Aug 1, 2030
Sparsentan Small MoleculesMarketedNCT05856760Immunoglobulin A NephropathyApproved COMPLETED 478Oct 25, 2024
Sparsentan Small MoleculesMarketedNCT03493685Focal Segmental GlomerulosclerosisApproved COMPLETED 438Mar 19, 2026
RE-021, sparsentan Small MoleculesMarketedNCT01613118Focal Segmental GlomerulosclerosisApproved COMPLETED 109Mar 25, 2024
Unlock the TVTX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every TVTX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
FILSPARI
PriorityAccelerated
IgA nephropathyPhase 22026-10-02complete proteinuria remission: 75%; e GFR decline: -1.75 mL/min/1.73 m²; chronic e GFR slope: -1.11 mL/min/1.73 m²/year; total e GFR slope: -1.54 mL/min/1.73 m²/year; FSGS complete proteinuria remission: 20%; FSGS partial remission: 79%Read MoreTravere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026Read More
Scroll for more · summaries link to the source press release
Unlock every TVTX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock TVTX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Dube Eric MDirector, Officer (CHIEF EXECUTIVE OFFICER)Option 43,735 476,621 held$26.88 10/15/2026
Unlock the full TVTX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PERCEPTIVE ADVISORS LLC 3.6 % (12.5 %) 208.61 M 3.54 M -5.59% ( -209.66 K)
Unlock every fund holding TVTX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in TVTX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see TVTX ownership
Insider and institutional ownership, quarter by quarter.

TVTX Short Interest

Shares sold short, counted twice a month.

10.26%
Short % of Float
of tradable shares sold short
9.6M
Shares Sold Short
-12.4% vs prior count
4.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.0M
Avg Daily Volume
the average used for days to cover
Unlock TVTX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock TVTX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live TVTX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock TVTX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How TVTX ranks across every disease it competes in

Competitive Position is a premium feature
See how TVTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

TVTX News

TVTX
Nov 12, 2026
TVTXGeneral

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics announced inducement equity grants for 20 new employees on November 10, 2026. The grants consist of 65,520 restricted stock units (RSUs) that vest over four years. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract new talent to the company.

Read more →
TVTX
Nov 3, 2026
TVTXConferences/Events
▲ +6.1%on this news

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics announced its participation in several upcoming investor conferences. Management will present at the Guggenheim Global Healthcare Conference on November 10, 2026, and at other events throughout November. Live webcasts of the presentations will be available on the company's investor page.

Read more →
TVTX
Nov 2, 2026
TVTXGeneral

Travere Therapeutics Reports Third Quarter 2026 Financial Results

Travere Therapeutics reported strong third quarter 2026 results with FILSPARI sales of $200 million, marking a 120% increase year-over-year. The company is advancing its Phase 3 HARMONY Study for pegtibatinase, with topline results expected in late 2027. Civorebrutinib's IND submission is anticipated by year-end, supporting its development in immune-mediated kidney diseases.

Read more →
TVTX
Oct 26, 2026
TVTXConferences/Events

Travere Therapeutics to Report Third Quarter 2026 Financial Results

Travere Therapeutics will announce its third quarter 2026 financial results on November 2, 2026. The company plans to hold a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the information through the company's website.

Read more →
TVTX
Oct 23, 2026
TVTXPhases

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

Travere Therapeutics presented new biomarker data from the Phase 3 PROTECT Study at ASN Kidney Week, indicating that FILSPARI (sparsentan) may modify disease pathophysiology in IgA nephropathy (IgAN). The study showed that FILSPARI achieved greater reductions in kidney inflammation biomarkers compared to irbesartan, supporting its use as a first-line treatment. These findings align with previous PROTECT results demonstrating superior proteinuria reduction.

Read more →
TVTX
Oct 2, 2026
TVTXConferences/Events

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Travere Therapeutics announced it will present nine new data presentations at ASN Kidney Week 2026, including five oral presentations. The data focuses on the efficacy of FILSPARI® (sparsentan) in treating patients with IgA nephropathy and focal segmental glomerulosclerosis. The final SPARTAN analysis is expected to provide significant insights into the treatment's potential.

Read more →
TVTX
Sep 23, 2026
TVTXFDA Updates

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics has received a Notice of Allowance from the USPTO for its patent application concerning methods of using FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS). This patent, once issued, will provide U.S. patent protection for specific applications of the drug, potentially strengthening the company's market position in the treatment of kidney diseases.

Read more →
TVTX
Sep 21, 2026
TVTXGeneral

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Travere Therapeutics announced the resignation of CEO Eric Dube, who is stepping down to focus on his health and family. The Board of Directors has appointed Bradley L. Campbell, the former CEO of Amicus Therapeutics, as the new president and CEO. This leadership change reflects the company's commitment to continuity and experienced management.

Read more →
TVTX
Sep 17, 2026
TVTXConferences/Events

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

Travere Therapeutics will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026. The presentation will be accessible via a live webcast on the company's investor page, with a replay available for 30 days post-event. This engagement underscores Travere's commitment to addressing the needs of the rare disease community.

Read more →
TVTX
Aug 4, 2026
TVTXGeneral
▲ +12%on this news

Travere Therapeutics Reports Second Quarter 2026 Financial Results

Travere Therapeutics has reported its financial results for the second quarter of 2026, highlighting a strong performance that indicates a period of growth for the company. CEO Eric Dube emphasized the disciplined execution of their strategies, which has contributed to their success. The report suggests optimism for both immediate and future prospects.

Read more →
TVTX
Jul 28, 2026
TVTXConferences/Events

Travere Therapeutics to Report Second Quarter 2026 Financial Results

Travere Therapeutics, Inc. has announced that it will report its second quarter 2026 financial results on August 4, 2026, after U.S. markets close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Archived access to the call will be available for 30 days on their website.

Read more →
TVTX
Jun 16, 2026
TVTXGeneral

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics has announced the planned retirement of its Chief Research Officer in 2027. This decision marks a significant transition for the company as it prepares for future leadership changes. The announcement comes as part of the company's ongoing strategic planning efforts.

Read more →
TVTX
Jun 4, 2026
TVTXPhases

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics presented long-term open-label extension data from the Phase 3 DUPLEX study at the 63rd European Renal Association Congress. This study highlights the ongoing research into treatments for rare kidney diseases. Additionally, the company announced an exclusive licensing agreement with Everest Medicines for Civorebrutinib, a promising BTK inhibitor.

Read more →
TVTX
Jun 2, 2026
TVTXGeneral

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Travere Therapeutics has entered into an exclusive licensing agreement with Everest Medicines for Civorebrutinib, a potential best-in-class BTK inhibitor aimed at treating rare kidney diseases. This partnership may enhance the development and commercialization of the drug in targeted markets. Further details about the agreement and its implications for both companies are yet to be disclosed.

Read more →

About Travere Therapeutics, Inc.

San Diego, CA 497 employees travere.com
Headquarters3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE
Trade the next TVTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime